{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:05:30Z","timestamp":1778904330296,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1007\/s12094-008-0254-7","type":"journal-article","created":{"date-parts":[[2008,9,27]],"date-time":"2008-09-27T13:18:26Z","timestamp":1222521506000},"page":"583-586","source":"Crossref","is-referenced-by-count":56,"title":["Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer"],"prefix":"10.1007","volume":"10","author":[{"given":"Jos\u00e9 Miguel","family":"Jurado Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bella","family":"Pajares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,28]]},"reference":[{"key":"254_CR1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A. Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43\u201366","journal-title":"CA Cancer J Clin"},{"key":"254_CR2","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"17","author":"R. Ozols","year":"2003","unstructured":"Ozols R, Bundy B, Creer B et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 17:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"254_CR3","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"A.N. Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III trial of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"},{"key":"254_CR4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0093-7754(01)90274-X","volume":"28","author":"R.F. Ozols","year":"2001","unstructured":"Ozols RF (2001) The current role of gemcitabine in ovarian cancer. Semin Oncol 28:18\u201324","journal-title":"Semin Oncol"},{"key":"254_CR5","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","volume":"20","author":"M. Markman","year":"2002","unstructured":"Markman M, Hall J, Spitz D et al (2002) Phase II trial of weekly single agent paclitaxel in platinum\/paclitaxel refractory ovarian cancer. J Clin Oncol 20:2365\u20132369","journal-title":"J Clin Oncol"},{"key":"254_CR6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/gyno.1998.5243","volume":"72","author":"R.A. Burguer","year":"1999","unstructured":"Burguer RA, DiSaia PJ, Roberts JA et al (1999) Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol Oncol 72:148\u2013153","journal-title":"Gynecol Oncol"},{"key":"254_CR7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D. Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57\u201370","journal-title":"Cell"},{"key":"254_CR8","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0962-8924(01)82185-1","volume":"11","author":"C. Brahimi-Horn","year":"2001","unstructured":"Brahimi-Horn C, Berra E, Pouyss\u00e9gur J (2001) Hypoxia: the tumor\u2019s gateway to progression along the angiogenic pathway. Trends Cell Biol 11:S32\u2013S36","journal-title":"Trends Cell Biol"},{"key":"254_CR9","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"H.F. Dvorak","year":"2002","unstructured":"Dvorak HF (2002) Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368","journal-title":"J Clin Oncol"},{"key":"254_CR10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.1997.537","volume":"76","author":"S. Yamamoto","year":"1997","unstructured":"Yamamoto S, Konishi I, Mandai M et al (1997) Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221\u20131227","journal-title":"Br J Cancer"},{"key":"254_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3835(97)00350-9","volume":"121","author":"E.M. Hartenbach","year":"1997","unstructured":"Hartenbach EM, Olson TA, Goswitz JJ et al (1997) Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121:169\u2013175","journal-title":"Cancer Lett"},{"key":"254_CR12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1054\/bjoc.2000.1228","volume":"83","author":"G.H. Shen","year":"2000","unstructured":"Shen GH, Ghazizadeh M, Kawanami O et al (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196\u2013203","journal-title":"Br J Cancer"},{"key":"254_CR13","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N. Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W et al (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328\u2013335","journal-title":"Biochem Biophys Res Commun"},{"key":"254_CR14","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1158\/1078-0432.CCR-05-0910","volume":"11","author":"L. Hu","year":"2005","unstructured":"Hu L, Hofmann J, Holash J et al (2005) Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11:6966\u20136971","journal-title":"Clin Cancer Res"},{"key":"254_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/bies.950130106","volume":"13","author":"R.S. Kerbel","year":"1991","unstructured":"Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13:31\u201336","journal-title":"Bioessays"},{"key":"254_CR16","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0959-8049(00)00092-7","volume":"36","author":"R.S. Kerbel","year":"2000","unstructured":"Kerbel RS, Viloria-Petit A, Klement G et al (2000) Accidental anti-angiogenic drugs: antioncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36:1248\u20131257","journal-title":"Eur J Cancer"},{"key":"254_CR17","first-page":"7501","volume":"61","author":"L. Bello","year":"2001","unstructured":"Bello L, Carrabba G, Giussani C et al (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61:7501\u20137506","journal-title":"Cancer Res"},{"key":"254_CR18","first-page":"2731","volume":"62","author":"S. Man","year":"2002","unstructured":"Man S, Bocci G, Francia G et al (2002) Antitumor effects in mice of low dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731\u20132735","journal-title":"Cancer Res"},{"key":"254_CR19","doi-asserted-by":"crossref","first-page":"1s","DOI":"10.1007\/s10549-005-0322-y","volume":"92","author":"H.J. Burstein","year":"2005","unstructured":"Burstein HJ, Spiegel D, Kindsvogel K et al (2005) Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 92:1s [suppl abstr 4]","journal-title":"Breast Cancer Res Treat"},{"key":"254_CR20","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","volume":"25","author":"R.A. Burguer","year":"2007","unstructured":"Burguer RA, Sill M, Monk B et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol 25:5165\u20135171","journal-title":"J Clin Oncol"},{"key":"254_CR21","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","volume":"25","author":"S.A. Cannistra","year":"2007","unstructured":"Cannistra SA, Matulonis UA, Penson RT et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180\u20135186","journal-title":"J Clin Oncol"},{"key":"254_CR22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"A.A. Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G et al (2008) Phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian cancer (OC): a Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 26:76\u201382","journal-title":"J Clin Oncol"},{"key":"254_CR23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P. Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"254_CR24","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","volume":"19","author":"G.J. Rustin","year":"2001","unstructured":"Rustin GJ, Marples M, Nelstrop AE et al (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19:4054\u20134057","journal-title":"J Clin Oncol"},{"issue":"[10Suppl]","key":"254_CR25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2003.01.223","volume":"21","author":"G.J. Rustin","year":"2003","unstructured":"Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21[10 Suppl]:187\u2013193","journal-title":"J Clin Oncol"},{"key":"254_CR26","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H. Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluoracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"254_CR27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21969","volume":"107","author":"J.D. Wright","year":"2006","unstructured":"Wright JD, Hagemann A, Rader JS et al (2006) Bevacizumab combination therapy in recurrent, platinum-refractory epithelial ovarian carcinoma. Cancer 107:83\u201389","journal-title":"Cancer"},{"key":"254_CR28","doi-asserted-by":"crossref","unstructured":"Koner JA, Fallon K, Pezulli S et al (2007) A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis) and IV bevazicumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol 25[Suppl] [Abstract 5523]","DOI":"10.1200\/jco.2007.25.18_suppl.5523"},{"key":"254_CR29","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2007.12.1509","volume":"25","author":"R.A. Burguer","year":"2007","unstructured":"Burguer RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25:2902\u20132908","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-008-0254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-008-0254-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-008-0254-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T17:13:22Z","timestamp":1588958002000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-008-0254-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["254"],"URL":"https:\/\/doi.org\/10.1007\/s12094-008-0254-7","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}